We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+3.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.89B
AUM Growth
+$345M
Cap. Flow
-$69.9M
Cap. Flow %
-2.42%
Top 10 Hldgs %
30.33%
Holding
133
New
31
Increased
28
Reduced
22
Closed
15

Top Buys

Rank Stock Value
1
QTTB icon
Q32 Bio
QTTB
+$97.6M
2
CNC icon
Centene
CNC
+$61.3M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$51.5M
4
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
+$41.1M
5
CVS icon
CVS Health
CVS
+$39.5M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$52.4M
2
GKOS icon
Glaukos
GKOS
+$51.5M
3
PODD icon
Insulet
PODD
+$41.5M
4
MCK icon
McKesson
MCK
+$38.1M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$35.8M

Sector Composition

Rank Sector Weight
1 Healthcare 74.89%
2 Financials 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
51
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$16.5M 0.57%
126,895
– –
PTLA
52
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$16.3M 0.57%
+500,000
New +$21.9M
PTLA
53
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$16.3M 0.57%
+500,000
New +$21.9M
VYNE icon
54
VYNE Therapeutics
VYNE
$340K
$16M 0.56%
+5,927
New +$14.4M
CBAY
55
DELISTED
Cymabay Therapeutics
CBAY
$15.8M 0.55%
+1,213,181
New +$15.1M
PODD icon
56
Insulet
PODD
$11.3B
$14.8M 0.51%
171,000
-534,573
-76% -$41.5M
EHTH icon
57
eHealth
EHTH
$42.5M
$14.8M 0.51%
1,030,802
+16,886
+2% +$278K
GTHX
58
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$13.8M 0.48%
+373,000
New +$9.95M
MOH icon
59
Molina Healthcare
MOH
$10.3B
$13.6M 0.47%
168,000
-400,000
-70% -$32.2M
IMMU
60
DELISTED
Immunomedics Inc
IMMU
$13.6M 0.47%
930,448
-370,000
-28% -$6.05M
ZBH icon
61
Zimmer Biomet
ZBH
$17.7B
$13.2M 0.46%
+124,630
New +$14.5M
ARDX icon
62
Ardelyx
ARDX
$1.24B
$13.1M 0.46%
2,602,733
+133,153
+5% +$831K
LKFT
63
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$13M 0.45%
130,000
– –
SYBX
64
DELISTED
Synlogic
SYBX
$12.8M 0.44%
91,010
+34,334
+61% +$5.32M
WMGI
65
DELISTED
Wright Medical Group Inc
WMGI
$12.6M 0.44%
+634,000
New +$13.6M
RYTM icon
66
Rhythm Pharmaceuticals
RYTM
$7B
$11.6M 0.4%
582,010
– –
SCTL
67
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$11.1M 0.39%
1,126,150
-994,229
-47% -$8.34M
WVE icon
68
Wave Life Sciences
WVE
$1.12B
$10.8M 0.37%
268,174
-46,500
-15% -$1.95M
PFNX
69
DELISTED
Pfenex Inc.
PFNX
$9.96M 0.35%
1,659,501
+829,285
+100% +$3.26M
IVTY
70
DELISTED
Invuity, Inc
IVTY
$9M 0.31%
2,336,889
+1,159,660
+99% +$5.3M
NVTA
71
DELISTED
Invitae Corporation
NVTA
$8.92M 0.31%
1,901,788
+178,788
+10% +$1.28M
RETA
72
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8M 0.28%
390,000
– –
OPCH icon
73
Option Care Health
OPCH
$3.4B
$7.68M 0.27%
781,000
– –
RGNX icon
74
Regenxbio
RGNX
$623M
$7.65M 0.27%
256,300
– –
RCKT icon
75
Rocket Pharmaceuticals
RCKT
$348M
$7.5M 0.26%
+400,000
New +$6.52M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2018 Portfolio in Review

As of Q1 2018, Deerfield Management held 133 positions worth $2.89B, up 14% from $2.54B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Deerfield Management's Q1 2018 filing shows 31 new, 28 increased, 22 reduced and 15 closed positions. Its largest new stake was Q32 Bio: 290,391 shares worth $97.7M. The largest sale was DexCom, an estimated $52.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Financials.

  • Deerfield Management's largest Q1 2018 buy was Q32 Bio: 290,391 shares worth $97.7M.
  • Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q1 2018, an estimated $51.5M increase.
  • Deerfield Management's biggest Q1 2018 reduction was DexCom, cutting an estimated $52.4M.
  • Deerfield Management fully exited Revance Therapeutics, Inc. in Q1 2018, selling an estimated $35.8M.
  • Deerfield Management's ten largest holdings make up 30% of its $2.89B portfolio in Q1 2018.
  • Deerfield Management opened 31 new positions and closed 15 in Q1 2018.
  • Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.89B.

Based on Deerfield Management's 13F filing for Q1 2018, filed 15 May 2018.